Pharma BD Deal Intelligence

Mallinckrodt plc / Sucampo Pharmaceuticals, Inc.

2017 · Acquisition/Merger · $1.2B · Complete

Announcement Sentiment

Neutral / mixed

Mallinckrodt agreed to acquire Sucampo Pharmaceuticals via tender offer at $18.00/share in cash, total transaction value approximately $1.2B. The deal added Sucampo's lead commercial product Amitiza (chronic constipation) plus two Phase 3 rare disease assets: CPP-1X/sulindac for familial adenomatous polyposis and VTS-270 for Niemann-Pick Type C. Closed Q1 2018.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Dec 26, 2017
Closed Feb 13, 2018
Deal value $1.2B
Deal type Acquisition/Merger
Therapeutic area Chronic constipation/IBS-C (Amitiza); rare diseases (FAP, NPC)
Indications Chronic constipation/IBS-C (Amitiza); rare diseases (FAP, NPC)
Key assets Amitiza (lubiprostone); CPP-1X/sulindac (familial adenomatous polyposis); VTS-270 (Niemann-Pick Type C)
Mechanism Chloride channel activator (Amitiza); rare disease pipeline

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals